FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Healio4h
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
BioSpace7h
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
psychiatryadvisor.com16h
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
Hosted on MSN39m
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
Managed Healthcare Executive15h
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Hosted on MSN3h
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
WRVO18h
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
pharmaphorum3d
J&J builds case for antidepressant Spravato with head-to-head trial
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.
pharmaphorum1d
J&J’s Spravato for depression ‘should be much cheaper’
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...